[{"id":"bb7dd126-5213-42ac-be7a-cb85b653508e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03003468","created_at":"2021-01-18T14:46:25.071Z","updated_at":"2025-02-25T16:05:37.605Z","phase":"Phase 1/2","brief_title":"Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017","source_id_and_acronym":"NCT03003468","lead_sponsor":"Lawrence Feldman, MD","biomarkers":" ALK","pipe":" | ","alterations":" EGFR mutation • ALK mutation","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Imprime PGG (odetiglucan)"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 07/11/2017","start_date":" 07/11/2017","primary_txt":" Primary completion: 11/22/2021","primary_completion_date":" 11/22/2021","study_txt":" Completion: 11/28/2022","study_completion_date":" 11/28/2022","last_update_posted":"2024-08-13"},{"id":"54f982d0-0cfa-4202-bfc7-67e5ec733733","acronym":"","url":"https://clinicaltrials.gov/study/NCT02981303","created_at":"2021-01-18T14:39:55.500Z","updated_at":"2025-02-25T16:05:30.757Z","phase":"Phase 2","brief_title":"Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer","source_id_and_acronym":"NCT02981303","lead_sponsor":"HiberCell, Inc.","biomarkers":" HER-2 • PD-L1 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Imprime PGG (odetiglucan)"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 02/22/2017","start_date":" 02/22/2017","primary_txt":" Primary completion: 12/31/2020","primary_completion_date":" 12/31/2020","study_txt":" Completion: 12/31/2020","study_completion_date":" 12/31/2020","last_update_posted":"2024-07-09"},{"id":"a06b4240-2997-4ef2-a868-1a44f43ce1b2","acronym":"MK-3475-C99","url":"https://clinicaltrials.gov/study/NCT05159778","created_at":"2021-12-16T13:53:29.380Z","updated_at":"2025-02-25T16:17:03.472Z","phase":"Phase 2","brief_title":"Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)","source_id_and_acronym":"NCT05159778 - MK-3475-C99","lead_sponsor":"HiberCell, Inc.","biomarkers":" HER-2 • PD-L1 • ER • PIK3CA • PGR • CD86","pipe":" | ","alterations":" PIK3CA mutation","tags":["HER-2 • PD-L1 • ER • PIK3CA • PGR • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Imprime PGG (odetiglucan)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 11/09/2021","start_date":" 11/09/2021","primary_txt":" Primary completion: 03/22/2023","primary_completion_date":" 03/22/2023","study_txt":" Completion: 04/12/2023","study_completion_date":" 04/12/2023","last_update_posted":"2023-06-22"},{"id":"dc88e68f-f782-4d5a-b32b-216a22465e77","acronym":"","url":"https://clinicaltrials.gov/study/NCT01269385","created_at":"2021-01-18T05:07:58.484Z","updated_at":"2024-07-02T16:36:43.905Z","phase":"Phase 1/2","brief_title":"Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT01269385","lead_sponsor":"Mayo Clinic","biomarkers":" CD20 • CCND1 • IGH • CD38 • CD5 • FCER2","pipe":" | ","alterations":" CD38 expression • CD20 expression","tags":["CD20 • CCND1 • IGH • CD38 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression • CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Campath (alemtuzumab) • Imprime PGG (odetiglucan)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 01/01/2011","start_date":" 01/01/2011","primary_txt":" Primary completion: 06/01/2014","primary_completion_date":" 06/01/2014","study_txt":" Completion: 06/01/2015","study_completion_date":" 06/01/2015","last_update_posted":"2020-06-23"}]